Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections

American Journal of Clinical Pathology

Volumn 113, Issue 3, 2000, Pages 369-373

  Vis, André N ^a   Kranse, Ries ^b   Nigg, Alex L ^b   Van Der Kwast, Theo H ^b  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b NONE

Author keywords

Antigenicity; Immunohistochemistry; Method; Paraffin slides; Prognostic marker; Prostate

Indexed keywords

ANDROGEN RECEPTOR; HERMES ANTIGEN; PROTEIN P27;

ANTIGENICITY; ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; TISSUE PRESERVATION;

EID: 0034049106     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/cqwy-e3f6-9kdn-yv36     Document Type: Article

References (14)

1. Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 1996;88:1054-1059.
2. Prioleau J, Schnitt SJ. p53 antigen loss in stored paraffin slides [letter]. N Engl J Med. 1995;332:1521-1522.
3. Bertheau P, Cazals-Hatem P, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol. 1998;51:370-374.
4. Manne U, Myers RB, Srivastava S, et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer [letter]. J Natl Cancer Inst. 1997;89:585-586.
5. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998;58:542-548.
6. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159:941-945.
7. Cote RJ, Shi Y, Groshen S, et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst. 1998;90:916-920.
8. Bubendorf L, Sauter G, Moch H, et al. Ki67 lahelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol. 1996;178:437-441.
9. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996;156: 1064-1068.
10. Stattin P, Damber JE, Karlberg L, et al. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol. 1997;157:219-222.
11. Bubendorf L, Tapia C, Gasser TC, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol. 1998;29:949-954.
12. Noordzij MA, Bogdanowicz JF, van Krimpen C, et al. The prognostic value of pretreatment expression of androgen receptor and hcl-2 in hormonally treated prostate cancer patients. J Urol. 1997;158:1880-1885.
13. Noordzij MA, van Steenbrugge GJ, Verkaik NS, et al. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res. 1997;3: 805-815.
14. Janssen PJ, Brinkmann AO, Boersma WJ, et al. Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pretreatment. J Histochem Cytochem. 1994;42:1169-1175.